

Johnson & Johnson's submitted statements to Axios

We appropriately and responsibly met all laws and regulations on the manufacturing, sale and distribution of APIs (active pharmaceutical ingredients) and the raw materials that go into them, which are highly controlled by regulatory and law enforcement agencies around the world. These APIs were used in the manufacturing of opioid medicines prescribed by doctors for patients needing pain relief in accordance with all FDA regulations. As a supplier of APIs and in line with the role of API manufacturers in general, Noramco did not play a role in the commercialization of the finished product that came from their customers. Noramco was one of a number of suppliers of these types of APIs.

Our actions in the marketing and promotion of these important prescription pain medications were appropriate and responsible – and that will be apparent to the jurors who will hear the evidence at trial. The FDA-approved labels for these prescription pain medications provide clear information about their risks and benefits. The allegations made against our company are baseless and unsubstantiated. In fact, since 2008, our opioid medications have accounted for less than one percent of the U.S. market for this class of medications (including generics).

Opioid abuse and addiction are serious public health issues. We are committed to being part of the ongoing dialogue and to doing our part to find ways to address this crisis.